Italy and San Marino's treaty on IP recognition seems to be over. But what about existing rights, Jeremy asks on behalf of a concerned [and now better-informed] reader
* Problems and imperfections in biotech patenting: realities on the ground and trying to fix the system
This is the last post in this series of six on biotech, which Suleman has kindly written for the happiness of both patent and non-patent enthusiasts. The earlier posts can be found here (introductory), here (ethics), here (case law), here (strategies for protecting biotech inventions) and here (financing). This post summarises the issues of drug prices and access to medicines, which received the most comments from readers of the previous posts.
Katfriends Elisabetta Mina and Marina Lanfranconi (MILA Legal) write about an intriguing case recently decided by the District Court of Milan and concerning unauthorised use of evocative elements of Audrey Hepburn's image in an advertisement.
* Spanish Supreme Court asks: does compensation for moral prejudice tie in with lump sum IP infringement damages?
Valentina reports on a new reference to the Court of Justice of the European Union (CJEU) as to compensation for damage by means of the reasonable-royalty criterion and restoration of moral prejudice.
* "Fool's errand": no need to create your own brand if you can use someone else's Jeremy notes Speciality European Pharma Ltd v Doncaster Pharmaceuticals Group Ltd & Madaus GmbH  EWCA Civ 54 [on which see earlier katpost here], a trade mark infringement decision of the Court of Appeal, England and Wales, on parallel importation and over-stickering of pharmaceutical products.
Jeremy reviews The Logic of Innovation: Intellectual Property, and What the User Found There, from emeritus Kat and eminent academic Johanna Gibson (Herchel Smith Professor of Intellectual Property Law, Queen Mary University of London) and the fourth edition of Tritton on Intellectual Property in Europe, the standard work named after Katfriend and greatly ironic soul Guy Tritton (Hogarth Chambers).
How come prestigious Italian food brands are often relegated to serving as a mere private label manufacturer for the benefit of foreign mega-retailers, wonders Neil.
* Bayer feels the pain: branded Naproxen can't invoke the territoriality principle
Katfriend Marty Schwimmer reports on Belmora LLC v Bayer Consumer Care AG and Bayer Healthcare LLC, 1:14-cv-00847-GBL (EDVA Feb. 6, 2015), a recent US District Court for the Eastern District of Virginia ruling that deals with Article 6bis of the Paris Convention in the US as it applies to Bayer’s trade mark ‘FLANAX’.
CET-J is an independent group of 15 trade mark judges from Austria, Hungary, Germany, Netherlands, Switzerland, Turkey, France the United Kingdom, Portugal, Italy, Germany, and OHIM. As Jeremy recounts, the group is open both to new judges joining its meetings and sponsors.
Katfriend Richard Kempner discusses Fresh Trading Limited v Deepend Fresh Recovery Limited and Andrew Thomas Robert Chappell  EWHC 52 (Ch), a Chancery Division, England and Wales, decision addressing the copyright ownership in the ‘Dude’, ie the logo used on Innocent’s smoothie bottle in the past 15 years.
While the copyright dispute involving Robin Thicke and Marvin Gaye [see here and here] is entering the trial phase, Tom sinks his paws in the world of infringement in the music industries, between occasional similarities and copies that go beyond mere coincidence.
Merpel has it from an unimpeachable source that earlier last week, there was an informal get-together of European Patent Office's Administrative Council chairman. She couldn’t wait to tell the IPKat readers what that is about.
* To Kill a Mockingbird; the challenge where where sequel is prequel Many decades after the publication of To Kill a Mockingbird, Harper Lee’s lawyer said they had just found an unpublished sequel of that classic novel, which will be launched in July 2015. Some say Ms Lee is currently not in full control of her mind; some say the sequel is not entirely genuine -- and these are not the only tricky issues surrounding this tale, recounts Neil.
As President Obama announces significant investments to ‘pioneer a new model of patient-powered research’, Biotech Kat Suleman seizes the chance to revisit the topic of personalized medicine [on which he previously enlightened the readership here].
PREVIOUSLY, ON NEVER TOO LATE
Never too late 32 [week ending Sunday 8 February] –- Brazilian PTO’s delays | The Research Handbook on International Intellectual Property reviewed | Laura Smith-Hewitt | IP, women and leadership: the poll responses | Decline of West’s trust in innovation | Wikipedia public domain photos |CJEU in Case C-383/12 P Environmental Manufacturing LLP v OHIM | The Nordic IP Forum | The future of EPO’s BoA | Warner-Lambert v Actavis Mark 2 | Dragons' Den: where entertainment meets mis-advice? | Hospira v Genetech Mark 1, the Appeal | Litigation-Proof Patents: Avoiding the Most Common Patent Mistakes and Patent Portfolios: Quality, Creation, and Cost reviewed | Italy and San Marino’s friendship on IP is over| Problems and imperfections in biotech patenting: realities on the ground and trying to fix the system.
Never too late 31 [week ending Sunday 1 February] -- Women in IP, a MIP’s perspective | Another linking reference to the CJEU | Catarina Holtz on Disciplinary authority over the EPO BoA | EPO pays to say that patent examiners’ life is truly cool | You can’t name your daughter ‘Nutella’ | CJEU in Arne Forsgren v Österreichisches Patentamt | Blocking injunctions in Greece | IPEC and bondage in Haiss v Ball | Present and future of patent profession | Belgium asks CJEU: does the Enforcement Directive allow cost-capping in IP litigation? | Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency.
Never too late 30 [week ending Sunday 25 January] -- Julia Reda’s EU copyright revolution | GC on trade-marketing bottle shapes in (T-69/14 and T-70/14) | IPKat and BLACA’s event on Sensory copyright | IP Cross-Border Enforcement | US Supreme Court in Teva v Sandoz | On-line copyright infringement in Spain | GC on the ‘Pianissimo’ trade mark for vacuum cleaners in Case T‑11/14 Grundig Multimedia AG v OHIM | Judicial Independence - the EPO Responds to Sir Robin Jacob's Letter | Second medical use claims, skinny labels, and public policy in Warner-Lambert Company, LLC v Actavis Group Ptc EHF & Others | CJEU on exhaustion of copyright in Case C-419/13 Art & Allposters | CJEU confirms accessibility jurisdiction criterion for copyright infringement cases in Hejduk | the Court of Appeal for England and Wales takes Rihanna’s passing off claim under its umbrella | EPO invites its examiners to perform non-examining functions | Trade mark troubles in the Galapagos Islands | C5's 7th Forum on "Pharma & Biotech Patent Litigation" | Strategies for patenting biotech inventions | US Court of Appeals on first-sale doctrine in Omega v Costco.
Never too late 29 [week ending Sunday 18 January] -- Martin Luther King’s movie ‘Selma’ and copyright problems | CJEU’s copyright decisions awaited in 2015 | The Modern Law of Patents reviewed | China becoming a ‘protector’ of patent rights | ‘Je suis charlie’ trade mark in France and OHIM| UK IPO logo’s licensing system | High Court for England and Wales in Enterprise Holdings Inc v Europcar Group UK and Another  EWHC 17 (Ch) | Spain without Google News | CJEU on database protection in Case C-30/14 Ryanair | Can UPC and national law of infringement diverge? | GC on ‘Monaco’ trade mark in Case T-197/13 Monaco v OHIM | Corriere della Sera major infringement in Charlie Hebdo case | GoPro and Apple patent | Biotech patent case law.